Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy.
Park
Meyeon
M
Liu
Grant T
GT
Piltz-Seymour
Jody
J
Wisda
Catherine L
CL
Rook
Alain H
AH
Junkins-Hopkins
Jacqueline M
JM
Nasta
Sunita D
SD
Kim
Ellen J
EJ
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004167:Diphtheria Toxin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D018917:Optic Neuropathy, Ischemic / Q000139:chemically induced* / Q000175:diagnosis*; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D012307:Risk Factors; D012878:Skin Neoplasms / Q000188:drug therapy*; D014786:Vision Disorders / Q000139:chemically induced*
D000970:Antineoplastic Agents; D004167:Diphtheria Toxin; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox